[1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases

US7994172B2 · kind B2 · utility

Assignee

• Exelixis, Inc. · US

Inventors

• Ken Rice · Palo Alto, US
• Erick Wang Co · San Diego, US
• Moon Hwan Kim · Palo Alto, US
• Lynn Canne Bannen · Pacifica, US
• Joerg Bussenius · Foster City, US
• Donna Tra Le · San Jose, US
• Amy Lew Tsuhako · Milpitas, US
• John M. Nuss · Danville, US
• Yong Wang · South San Francisco, US
• Wei Xu · Saginaw, US
• Rhett Ronald Klein · Chicago, US

Key dates

• Filing date: Dec 27, 2005
• Grant date: Aug 9, 2011
• Expiry date: Aug 25, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.